---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029038"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:56:27.336501+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma FY2024 net loss $96.9M; cash burn continues; ATH-1105 Phase 1 complete; fosgonimeton paused

## Summary
- Cash, cash equivalents and investments $51.3M as of Dec 31, 2024, down from $147.4M; net cash used in operations $97.2M.
- Net loss $96.9M ($2.52 per share) vs $117.7M ($3.09 per share) in 2023; R&D expenses $70.7M, G&A $26.1M.
- Legal expense $4.1M accrued for settlement with DOJ related to NIH grant.
- ATH-1105 Phase 1 in 80 healthy volunteers completed with favorable safety; on track to dose ALS patients in 2025.
- LIFT-AD Phase 2/3 of fosgonimeton missed endpoints; development paused; exploring strategic alternatives with Cantor Fitzgerald.

## SEC filing metadata
- accession: 0000950170-25-029038
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017025029038/0000950170-25-029038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017025029038/atha-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029038
- JSON: https://secwatch.observer/filing/0000950170-25-029038.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.